Literature DB >> 22231380

Update on clinical aspects and treatment of selected vitamin-responsive disorders II (riboflavin and CoQ 10).

Rita Horvath1.   

Abstract

Riboflavin and ubiquinone (Coenzyme Q(10), CoQ(10)) deficiencies are heterogeneous groups of autosomal recessive conditions affecting both children and adults. Riboflavin (vitamin B(2))-derived cofactors are essential for the function of numerous dehydrogenases. Genetic defects of the riboflavin transport have been detected in Brown-Vialetto-Van Laere and Fazio-Londe syndromes (C20orf54), and haploinsufficiency of GPR172B has been proposed in one patient to cause persistent riboflavin deficiency. Mutations in the electron tranferring fravoprotein genes (ETFA/ETFB) and its dehydrogenase (ETFDH) are causative for multiple acyl-CoA dehydrogenase deficiency. Mutations in ACAD9, encoding the acyl-CoA dehydrogenase 9 protein were recently reported in mitochondrial disease with respiratory chain complex I deficiency. All these conditions may respond to riboflavin therapy. CoQ(10) is a lipid-soluble component of the cell membranes, where it functions as a mobile electron and proton carrier, but also participates in other cellular processes as a potent antioxidant, and by influencing pyrimidine metabolism. The increasing number of molecular defects in enzymes of the CoQ(10) biosynthetic pathways (PDSS1, PDSS2, COQ2, COQ6, COQ9, CABC1/ADCK3) underlies the importance of these conditions. The clinical heterogeneity may reflect blocks at different levels in the complex biosynthetic pathway. Despite the identification of several primary CoQ(10) deficiency genes, the number of reported patients is still low, and no true genotype-phenotype correlations are known which makes the genetic diagnosis still difficult. Additionally to primary CoQ(10) deficiencies, where the mutation impairs a protein directly involved in CoQ(10) biosynthesis, we can differentiate secondary deficiencies. CoQ(10) supplementation may be beneficial in both primary and secondary deficiencies and therefore the early recognition of these diseases is of utmost importance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22231380     DOI: 10.1007/s10545-011-9434-1

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  42 in total

1.  162nd ENMC International Workshop: Disorders of muscle lipid metabolism in adults 28-30 November 2008, Bussum, The Netherlands.

Authors:  Pascal Laforêt; Christine Vianey-Saban; John Vissing
Journal:  Neuromuscul Disord       Date:  2010-03-23       Impact factor: 4.296

2.  Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations.

Authors:  Luis Carlos López; Markus Schuelke; Catarina M Quinzii; Tomotake Kanki; Richard J T Rodenburg; Ali Naini; Salvatore Dimauro; Michio Hirano
Journal:  Am J Hum Genet       Date:  2006-10-27       Impact factor: 11.025

3.  Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy.

Authors:  Sabrina Sacconi; Eva Trevisson; Leonardo Salviati; Ségolène Aymé; Odile Rigal; Alberto Garcia Redondo; Michelangelo Mancuso; Gabriele Siciliano; Paola Tonin; Corrado Angelini; Karine Auré; Anne Lombès; Claude Desnuelle
Journal:  Neuromuscul Disord       Date:  2009-11-27       Impact factor: 4.296

4.  Late-onset cerebellar ataxia with hypogonadism and muscle coenzyme Q10 deficiency.

Authors:  M Gironi; C Lamperti; R Nemni; M Moggio; G Comi; F R Guerini; P Ferrante; N Canal; A Naini; N Bresolin; S DiMauro
Journal:  Neurology       Date:  2004-03-09       Impact factor: 9.910

5.  Role of flavinylation in a mild variant of multiple acyl-CoA dehydrogenation deficiency: a molecular rationale for the effects of riboflavin supplementation.

Authors:  Bárbara J Henriques; João V Rodrigues; Rikke K Olsen; Peter Bross; Cláudio M Gomes
Journal:  J Biol Chem       Date:  2008-12-16       Impact factor: 5.157

6.  COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement.

Authors:  Francesca Diomedi-Camassei; Silvia Di Giandomenico; Filippo M Santorelli; Gianluca Caridi; Fiorella Piemonte; Giovanni Montini; Gian Marco Ghiggeri; Luisa Murer; Laura Barisoni; Anna Pastore; Andrea Onetti Muda; Maria Luisa Valente; Enrico Bertini; Francesco Emma
Journal:  J Am Soc Nephrol       Date:  2007-09-12       Impact factor: 10.121

7.  ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency.

Authors:  Rikke K J Olsen; Simon E Olpin; Brage S Andresen; Zofia H Miedzybrodzka; Morteza Pourfarzam; Begoña Merinero; Frank E Frerman; Michael W Beresford; John C S Dean; Nanna Cornelius; Oluf Andersen; Anders Oldfors; Elisabeth Holme; Niels Gregersen; Douglass M Turnbull; Andrew A M Morris
Journal:  Brain       Date:  2007-06-20       Impact factor: 13.501

8.  CABC1 gene mutations cause ubiquinone deficiency with cerebellar ataxia and seizures.

Authors:  Julie Mollet; Agnès Delahodde; Valérie Serre; Dominique Chretien; Dimitri Schlemmer; Anne Lombes; Nathalie Boddaert; Isabelle Desguerre; Pascale de Lonlay; Hélène Ogier de Baulny; Arnold Munnich; Agnès Rötig
Journal:  Am J Hum Genet       Date:  2008-03       Impact factor: 11.025

9.  Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with deafness, is caused by mutations in c20orf54.

Authors:  Peter Green; Matthew Wiseman; Yanick J Crow; Henry Houlden; Shelley Riphagen; Jean-Pierre Lin; F Lucy Raymond; Anne-Marie Childs; Eamonn Sheridan; Sian Edwards; Dragana J Josifova
Journal:  Am J Hum Genet       Date:  2010-03-04       Impact factor: 11.025

10.  A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.

Authors:  Thomas Klopstock; Patrick Yu-Wai-Man; Konstantinos Dimitriadis; Jacinthe Rouleau; Suzette Heck; Maura Bailie; Alaa Atawan; Sandip Chattopadhyay; Marion Schubert; Aylin Garip; Marcus Kernt; Diana Petraki; Christian Rummey; Mika Leinonen; Günther Metz; Philip G Griffiths; Thomas Meier; Patrick F Chinnery
Journal:  Brain       Date:  2011-07-25       Impact factor: 13.501

View more
  23 in total

1.  Molecular and functional characterization of riboflavin specific transport system in rat brain capillary endothelial cells.

Authors:  Mitesh Patel; Ramya Krishna Vadlapatla; Dhananjay Pal; Ashim K Mitra
Journal:  Brain Res       Date:  2012-06-07       Impact factor: 3.252

Review 2.  Ataxia.

Authors:  Umar Akbar; Tetsuo Ashizawa
Journal:  Neurol Clin       Date:  2015-02       Impact factor: 3.806

3.  Clinical presentations of coenzyme q10 deficiency syndrome.

Authors:  Catarina M Quinzii; Valentina Emmanuele; Michio Hirano
Journal:  Mol Syndromol       Date:  2014-07

Review 4.  Therapies for mitochondrial diseases and current clinical trials.

Authors:  Ayman W El-Hattab; Ana Maria Zarante; Mohammed Almannai; Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2017-09-18       Impact factor: 4.797

Review 5.  Advances in drug therapy for mitochondrial diseases.

Authors:  Lufei Zhang; Zhaoyong Zhang; Aisha Khan; Hui Zheng; Chao Yuan; Haishan Jiang
Journal:  Ann Transl Med       Date:  2020-01

Review 6.  Nutritional Interventions for Mitochondrial OXPHOS Deficiencies: Mechanisms and Model Systems.

Authors:  Adam J Kuszak; Michael Graham Espey; Marni J Falk; Marissa A Holmbeck; Giovanni Manfredi; Gerald S Shadel; Hilary J Vernon; Zarazuela Zolkipli-Cunningham
Journal:  Annu Rev Pathol       Date:  2017-11-03       Impact factor: 23.472

7.  Combined isobutyryl-CoA and multiple acyl-CoA dehydrogenase deficiency in a boy with altered riboflavin homeostasis.

Authors:  Albina Tummolo; Piero Leone; Maria Tolomeo; Rita Solito; Matteo Mattiuzzo; Francesca Romana Lepri; Tania Lorè; Roberta Cardinali; Donatella De Giovanni; Simonetta Simonetti; Maria Barile
Journal:  JIMD Rep       Date:  2022-05-07

8.  Transcriptional regulation of the albumin gene depends on the removal of histone methylation marks by the FAD-dependent monoamine oxidase lysine-specific demethylase 1 in HepG2 human hepatocarcinoma cells.

Authors:  Dandan Liu; Janos Zempleni
Journal:  J Nutr       Date:  2014-04-17       Impact factor: 4.798

9.  Current progress in the therapeutic options for mitochondrial disorders.

Authors:  E Koňaříková; A Marković; Z Korandová; J Houštěk; T Mráček
Journal:  Physiol Res       Date:  2020-11-02       Impact factor: 1.881

Review 10.  Mitochondrial Transplantation as a Novel Therapeutic Strategy for Mitochondrial Diseases.

Authors:  Anna Park; Mihee Oh; Su Jeong Lee; Kyoung-Jin Oh; Eun-Woo Lee; Sang Chul Lee; Kwang-Hee Bae; Baek Soo Han; Won Kon Kim
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.